http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Arcturus Therapeutics to Present at the Following Investor Conferences in November
-
Arcturus Therapeutics (ARCT) Announces Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
-
Arcturus Announces Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
-
CSL Enters Licensing Agreement with Arcturus Therapeutics for Next Generation mRNA Vaccine Technology
-
Arcturus Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 9, 2022
-
Arcturus Therapeutics to Attend the Following Investor Conferences
-
Arcturus Therapeutics to Attend the Following Investor Conferences
-
Arcturus Announces $63.2 Million Award from the U.S. Government to Support Development of Self-amplifying mRNA Vaccine for Rapid Pandemic Influenza Response
-
Arcturus Therapeutics (ARCT) Reports Durability Data Against Omicron Variants, Including BA.5, at Six-Month Timepoint Following Booster with ARCT-154 COVID-19 Vaccine
-
Arcturus Reports Durability Data Against Omicron Variants, Including BA.5, at Six-Month Timepoint Following Booster with ARCT-154 COVID-19 Vaccine
-
Arcturus Therapeutics Announces Second Quarter 2022 Financial Update and Pipeline Progress
-
Arcturus Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 9, 2022
-
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Arcturus Therapeutics Announces First Quarter 2022 Financial Update and Pipeline Progress
-
Arcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster Trial
-
Arcturus Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on May 9, 2022
-
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Arcturus Therapeutics (ARCT) Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study
-
Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study
-
Arcturus Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit
-
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Arcturus Therapeutics to Participate in the Barclays Global Healthcare Conference
-
Arcturus Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Update and Pipeline Progress
-
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Arcturus Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on February 28, 2022
-
Arcturus Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
-
Arcturus Therapeutics (ARCT) Reports New Data Demonstrating Neutralizing Antibody Immune Response to the SARS-CoV-2 Omicron Variant from ARCT-154 and ARCT-165 Booster Clinical Trial
-
Arcturus Therapeutics Reports New Data Demonstrating Neutralizing Antibody Immune Response to the SARS-CoV-2 Omicron Variant from ARCT-154 and ARCT-165 Booster Clinical Trial
-
Arcturus Therapeutics (ARCT) Reports Update Data from ARCT-154 and ARCT-165 Booster Trial, Demonstrates Robust Neutralizing Antibody Responses to SARS-CoV-2 and Several Variants
-
Arcturus Therapeutics Updates Data from ARCT-154 and ARCT-165 Booster Clinical Trial Demonstrating Robust Neutralizing Antibody Responses to SARS-CoV-2 and Several Variants
-
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Krystal Biotech Appoints Jing Marantz, MD, PhD, MBA as Chief Business Officer and Rand Sutherland, MD, MPH to its Board of Directors
-
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Arcturus Therapeutics (ARCT) Reports New Data and Provides Additional Updates from ARCT-154 and ARCT-165 Clinical Trials
-
Arcturus Therapeutics Reports New Data and Provides Additional Updates from ARCT-154 and ARCT-165 Clinical Trials
-
Arcturus Therapeutics (ARCT) Appoints Jing Marantz to its Board
-
Arcturus Therapeutics Appoints Jing Marantz, M.D., Ph.D., M.B.A. to its Board of Directors
-
Arcturus Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference
-
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Arcturus Therapeutics Announces Third Quarter 2021 Financial Update and Pipeline Progress
-
Arcturus Therapeutics to Report Third Quarter 2021 Financial Results and Provide Corporate Update on November 8, 2021
-
Arcturus Therapeutics (ARCT) Announces New Management Appointments
-
Arcturus Therapeutics Announces Leadership Appointments
-
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Oth
-
Arcturus Therapeutics (ARCT) CEO Meets with President of Vietnam and CEO of Vingroup, Discusses Covid-19 Vaccine
-
Arcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of COVID-19 Vaccine Collaboration
-
Arcturus Therapeutics (ARCT) Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR mRNA Vaccine Targeting SARS-CoV-2 Delta Variant
-
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and
